NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody, Clone 5E5
- Host Species:
- Human
- Species Reactivity:
- Human; Cynomolgus Monkey
- Applications:
- WB; ELISA; Inhib; In Vitro; In Vivo; Antagonist
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.
Immunogen
Species Reactivity
Clonality
Host Species
Isotype
Clone Number
Applications
Storage
Research Use Only
Target
Official Name
Full Name
Alternative Names
Figure 1 is a graph showing the interference of ApoC3 antibodies on the binding of ApoC3 to dimyristoylphosphatidylcholine (DMPC).
ELISA microplates were coated with DMPC and incubated with ApoC3 and test anti-ApoC3 antibodies. Measure the amount of ApoC3 still attached to the plate using a biotinylated anti-ApoC3 polyclonal goat antibody following standard procedures for ELISA colorimetric assays.
Figure 2 shows the binding of ApoC3 to VLDL in the presence of anti-ApoC3 antibody.
Figure 3 is a graph showing that 14C7 and 13G7 attenuate the ability of ApoC3 to inhibit lipoprotein lipase (LPL) activity. 1
4C7, 13G7, 5E5, or 646 antibodies were incubated with lipid emulsion and purified ApoC3 protein. The production of non-esterified fatty acids (NEFA) was measured and the percentage of NEFA produced compared to that produced by ApoC3 but in the absence of anti-ApoC3 antibody was plotted.
Figure 4 is a set of graphs showing that certain anti-ApoC3 antibodies attenuate the ability of ApoC3 to inhibit very low density lipoprotein (VLDL) uptake by HepG2 cells.
Figure 5 shows antibody binding to human ApoC3 (huApoC3) or cvnomolgus monkey ApoC3 (cynoApoC3).
Figure 6 shows the postprandial triglyceride lowering effect of 5E5.
Mice receiving 3 × 10^11 AAV8-huApoC3 viral particles were administered either vehicle or 5E5 antibody. Oral doses of olive oil were given and triglyceride levels were measured over a period of time.
Figure 7 shows the postprandial triglyceride lowering effect of 5E5.
The area under curve ("AUC") was reduced by about 25% with 5E5 administration as compared to vehicle control with a p value of 0.030.
Figure 8 shows the postprandial triglyceride lowering effect of 5E5.
Serum ApoC3 levels were also measured over time.
Figure 9 shows the postprandial triglyceride lowering effect of 5E5.
5E5 antibody levels were also measured in a time course.
Figure 10 shows acceleration of ApoC3 and ApoB clearance from blood following subcutaneous injection of 5E5 antibody to mice expressing human ApoC3.
FIG is e graphed as percent difference from negative isotype control
Publications (0)
